Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Bugianesi

Showing results (231-240 of 293) with videos related to

Pageof 30
Sort By:
Cancer Medicine|July 6, 2017
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver diseaseBenedetta Donati, Alessandro Pietrelli, Piero Pingitore, et al.
Clinical and Molecular Hepatology|May 20, 2026
The Natural History and Individualized Prediction of Liver Stiffness-Based Fibrosis Risk in MASLDYu Shi, Ruoqi Zhou, Seung Up Kim, et al.
Hepatology (Baltimore, Md.)|December 10, 2017
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitisZobair M Younossi, Rohit Loomba, Mary E Rinella, et al.
Nature Communications|September 16, 2016
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis CKhaled Thabet, Anastasia Asimakopoulos, Maryam Shojaei, et al.
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 16, 2021
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysisJörn M Schattenberg, Jeffrey V Lazarus, Philip N Newsome, et al.
Hepatology (Baltimore, Md.)|December 10, 2017
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosisZobair M Younossi, Rohit Loomba, Quentin M Anstee, et al.
Science Translational Medicine|December 3, 2020
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosisOlivier Govaere, Simon Cockell, Dina Tiniakos, et al.
Free Radical Biology & Medicine|February 21, 2012
Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trialCarmela Loguercio, Pietro Andreone, Ciprian Brisc, et al.
JHEP Reports : Innovation in Hepatology|August 4, 2023
Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver diseaseGrazia Pennisi, Marco Enea, Mauro Viganò, et al.
Pageof 30

Showing results (231-240 of 293) with videos related to

Sort By:
Pageof 30
Cancer Medicine|July 6, 2017
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver diseaseBenedetta Donati, Alessandro Pietrelli, Piero Pingitore, et al.
Clinical and Molecular Hepatology|May 20, 2026
The Natural History and Individualized Prediction of Liver Stiffness-Based Fibrosis Risk in MASLDYu Shi, Ruoqi Zhou, Seung Up Kim, et al.
Hepatology (Baltimore, Md.)|December 10, 2017
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitisZobair M Younossi, Rohit Loomba, Mary E Rinella, et al.
Nature Communications|September 16, 2016
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis CKhaled Thabet, Anastasia Asimakopoulos, Maryam Shojaei, et al.
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 16, 2021
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysisJörn M Schattenberg, Jeffrey V Lazarus, Philip N Newsome, et al.
Hepatology (Baltimore, Md.)|December 10, 2017
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosisZobair M Younossi, Rohit Loomba, Quentin M Anstee, et al.
Science Translational Medicine|December 3, 2020
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosisOlivier Govaere, Simon Cockell, Dina Tiniakos, et al.
Free Radical Biology & Medicine|February 21, 2012
Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trialCarmela Loguercio, Pietro Andreone, Ciprian Brisc, et al.
JHEP Reports : Innovation in Hepatology|August 4, 2023
Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver diseaseGrazia Pennisi, Marco Enea, Mauro Viganò, et al.
Pageof 30